G

Genovis AB
STO:GENO

Watchlist Manager
Genovis AB
STO:GENO
Watchlist
Price: 24.55 SEK -1.6% Market Closed
Market Cap: 1.6B SEK
Have any thoughts about
Genovis AB?
Write Note

Genovis AB
Common Stock

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Genovis AB
Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
G
Genovis AB
STO:GENO
Common Stock
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
AddLife AB
STO:ALIF B
Common Stock
kr62m
CAGR 3-Years
2%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
BICO Group AB
STO:BICO
Common Stock
kr1.8m
CAGR 3-Years
12%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biotage AB
STO:BIOT
Common Stock
kr113m
CAGR 3-Years
7%
CAGR 5-Years
5%
CAGR 10-Years
2%
MedCap AB (publ)
STO:MCAP
Common Stock
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
M
Magle Chemoswed Holding AB
STO:MAGLE
Common Stock
kr540k
CAGR 3-Years
3%
CAGR 5-Years
40%
CAGR 10-Years
N/A
No Stocks Found

Genovis AB
Glance View

Market Cap
1.6B SEK
Industry
Life Sciences Tools & Services

Genovis AB engages in the research and development of enzyme products. The company is headquartered in Lund, Skane. The company went IPO on 2005-11-11. The firm offers products within two product portfolios, namely protein portfolio and nano portfolio. The protein portfolio develops products within the areas of cancer, inflammatory and autoimmune diseases. The portfolio comprises FabRICATOR, a genetically modified enzyme the cleaves antibodies in two parts, and IgGZERO, a protein that specifically cleaves the sugar molecules that occur naturally on antibodies. The products within the nano portfolio are primarily directed at the preclinical market. The firm markets and sells its products through dealers and distributors in the European, North American and Asian continents. As of December 31, 2011, it operated a wholly owned subsidiary, Eijdo Research AB.

GENO Intrinsic Value
27.4 SEK
Undervaluation 10%
Intrinsic Value
Price
G

See Also

Back to Top